October 8, 2008 - Ivivi Technologies Inc. said yesterday the FDA reopened the submission for an additional round of review for its SofPulse M-10, Roma and Torino II targeted pulsed electromagnetic field (tPEMF) products 510(k) submission, in response to the company’s appeal of the FDA’s earlier “not substantially equivalent” (NSE) decision.
